Source MDx Pipeline of Molecular Diagnostics

Leveraging its patented Precision Profile™ assay technology, Source MDx is developing and commercializing a robust pipeline of prognostic, predictive and early detection molecular diagnostic tests for multiple cancers, autoimmune and other inflammatory diseases. Through its network of clinical collaborations, the company is advancing its pipeline to improve the management of patient care and lower healthcare costs.

Oncology Pipeline

Source MDx is currently collaborating with leading clinical institutions and pharmaceutical companies to develop Precision Profile tests in seven cancers to improve early detection, predict aggressiveness of disease and more effectively stratify patients for drug response.

Autoimmune and Other Inflammatory Diseases Pipeline

Source MDx is conducting exploratory and clinical studies in multiple autoimmune and inflammatory diseases. This pipeline of Precision Profile assays and tests will serve to improve the diagnosis, assist in the appropriate selection of treatment and monitor the overall course of these chronic diseases.